The D-nano unit is aimed to design preclinical projects involving therapeutic/ prophylactic/ theranostic nanomedicines (nanomedicines = nanoparticles + active pharmaceutical ingredient). The projects at D-nano are focused on solving inflammatory noncommunicable diseases affecting the lungs, cardio vasculature and gastrointestinal tract, as well as infections (caused by parasites such as Chagas disease and leishmaniasis; or by bacteria such as Pseudomonas spp), and are preferably administered by mucosal (oral and respiratory) or topical route.
The nanomedicines at D-nano employ unique building blocks extracted from sustainable sources, that result in super-stable engineered nanoparticles capable of trigger phase transitions in response to stimuli, to cross the stratum corneum in the absence of permeation enhancers, or to endure the gastrointestinal transit and nebulization.
As a secondary type of building blocks, we use dendrimers to build polymer legos (tecto-dendrimers) used as delivery systems of drugs against skin tumours.
In a direct relationship with D-nano, in 3D-F three-dimensional models of biological barriers (skin, intestine, lung) to study the toxicity, penetration and efficacy of designed nanomedicines on the bases of the 3R principle: replacement, reduction and refinement of the use of animals for experimentation.